Upon the closing, ImmunityBio will assume all capital expenditure and hiring obligations of Athenex pursuant to its agreements with New York State. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. Proceeds from the sale will be used to service the Company’s debt obligations and for other general corporate purposes.
(NASDAQ: IBRX) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing. 12, 2022 (GLOBE NEWSWIRE) - Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc.
